Sandbox:Vellayat
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vellayat Ali M.B.B.S[2]
Overview
Glycogen Storage Disease Type IV
Synonyms: GSD IV, Andersen Disease, Brancher deficiency; Amylopectinosis; Glycogen Branching Enzyme Deficiency, Glycogenosis IV
Overview:
Historical Perspective:
- In 1952, B Illingworth and GT Cori observed accumulation of an abnormal glycogen (resembling amylopectin) in the liver of a patient with von Gierke’s Disease. They postulated this finding to a different type of enzymatic deficiency, and thus to a different type of glycogen storage disease.[1]
- In 1956, DH Andersen, an American pathologist and pediatrician, reported the first clinical case of the disease as "familial cirrhosis of the liver with storage of abnormal glycogen".[2]
- In 1966, BI Brown and DH Brown demonstrated the deficiency of glycogen branching enzyme (alpha-1,4-glucan: alpha-1,4-glucan 6-glycosyl transferase) in a case of Type IV glycogenosis.[3]
Classification:
Pathophysiology:
- Glycogen storage disease type IV is an autosomal recessive genetic disorder which results due to deficiency of glycogen branching enzyme (GBE).[4]
- The branching enzyme is a single polypeptide encoded by GBE1 gene.[5]
- During Glycogenesis, GBE introduces branches to growing glycogen chains by transferring α-1,4-linked glucose monomers from the outer end of a chain, into an α-1,6 position of the same or neighboring glycogen chain. [6]
- Deficiency of GBE affects the branching process, thus producing a polysaccharide with fewer branching points and longer outer chains which resembles amylopectin, and is known as polyglucosan. [7]
Histologic manifestations in glycogen storage disease type IV typically consist of intracytoplasmic non-membrane-bound inclusions containing abnormally branched glycogen (polyglucosan bodies) within hepatocytes and myocytes. PMID: 22305237
Effect on muscles: The reason for muscle weakness and atrophy in glycogenosis is still unclear, although it has been suggested that excessive protein catabolism occurs in myophosphorylase, debrancher and acid maltase deficiencies. PMID: 2934518
We report a female infant with classic hepatic form of glycogen storage disease type IV who demonstrated diffuse reticuloendothelial system involvement with the spleen, bone marrow, and lymph nodes infiltrated by foamy histiocytes with intracytoplasmic polyglucosan deposits. PMID: 22305237
Genetics:
- The GBE1 gene is located
- Glycogen storage disease type IV: novel mutations and molecular characterization of a heterogeneous disorder.
- Li SC, Chen CM, Goldstein JL, Wu JY, Lemyre E, Burrow TA, Kang PB, Chen YT, Bali DS. J Inherit Metab Dis. 2010 Dec; 33 Suppl 3:S83-90. Epub 2010 Jan 8
-
Clinical features:
https://www.ncbi.nlm.nih.gov/books/NBK5300/
GLYCOGEN STORAGE DISEASE TYPE IV
Glycogen storage disease type IV (GSD-IV; Andersen disease; Brancher deficiency; Amylopectinosis; Glycogen branching enzyme deficiency) was first described by Andersen[102] in 1956 as "familial cirrhosis of the liver with storage of abnormal glycogen" and, in 1966, a deficiency of amylo-1, 4 to 1, 6-transglucosidase (glycogen branching enzyme) was reported[103]. Without glycogen branching enzyme, the glycogen cannot be branched and abnormal glycogens resembling an amylopectin-like structure (polyglucosan), which is harmful for cells, accumulate in various tissues including hepatocytes and myocytes[104,105]. The gene of the enzyme was mapped to chromosome 3p12 in 1993[105]. Mutation in the same gene causes adult polyglucosan body disease. It represents 0.3% of all glycogen storage diseases, and is transmitted as an autosomal recessive trait[106].
Clinical Features:GSD-IV is clinically extremely heterogeneous, owing in part to variation in tissue involvement 104,106]. The existence of tissue specific isozymes may be responsible for remarkable phenotypic variability of the disease.
- In the classical hepatic form, the patient appears normal at birth. But the disease rapidly progresses, early in life, to cirrhosis, and causes death due to liver failure between 3 and 5 years of age[102]. Affected children present with failure to thrive, hepatosplenomegaly and cirrhosis in the first 18 mo of age. Rarely, the hepatic disease is non-progressive or slowly progressive[107]. In non-progressive hepatic form patients may present with hepatosplenomegaly and a mild elevation of serum transaminases. Generally patients do not show any further progression of disease and growth is normal and liver enzymes may return to normal[107].
- In multiple system involvement, the deficiency of the enzyme was detected in both muscle and the liver[108]. This includes peripheral myopathy with or without cardiomyopathy, neuropathy, and liver cirrhosis. The age of onset ranges from neonatal to adult age[109].
- The neuromuscular presentation is divided into 4 groups according to age at onset[110].
A. In perinatal (fetal) form, which may cause hydrops fetalis and polyhydroamnios, the affected baby shows arthrogryposis of the limbs due to akinesia[111]. The presence of cervical cystic hygroma during pregnancy may be a warning sign of the disease[106]. Prenatal diagnosis is possible by determining enzyme activity or chorionic villi sampling. Death is inevitable in the neonatal period. Liver cirrhosis and hepatic failure have not been described.
B. In congenital form, the patients have severe hypotonia, hyporeflexia, cardiomyopathy, depressed respiration and neuronal involvement[104,112-114]. Liver involvement is not severe and the child dies in early infancy. Childhood neuromuscular form presents with myopathy or cardiopathy starting at any age[110,115]. The main presenting symptoms are exercise intolerance, exertional dyspnea and congestive heart failure in progressed cases. The disorder may be limited to muscle tissue and serum creatine kinase may be normal.
C. In adult form, there is isolated myopathy or polyglucosan body disease. The symptoms begin at any age in adulthood and may resemble muscular dystrophies; progressive difficulty in walking, and proximal limb weakness which was greater in the arms than the legs. Upper and lower motor neurons are involved. The disease may present as pyramidal tetraparesis, peripheral neuropathy, early neurogenic bladder, extrapyramidal symptoms and seizures, and cognitive impairment terminating in dementia[111].
The diagnosis can be made by studying enzyme activity in erythrocytes[116,117]. Ultrastructural examination of the central nervous system and skeletal muscle reveals amylopectin-like inclusions both in neurons and muscular fibers. MRIshows white matter abnormalities[118]. Histological examination of the liver shows hepatocellular periodic-acid Schiff positive, diastase-resistant inclusions of the abnormal glycogen deposits (Figure (Figure3).3). The enzyme deficiency can usually be demonstrated in the liver, leukocytes, erythrocytes and fibroblasts although normal leukocyte enzyme activity may be detected in patients with cardioskeletal myopathy[104]. Microscopic examination of tissues, demonstration of enzyme deficiency and mutation analysis confirm the diagnosis of GSD-IV[104,112].
Figure 3
Glycogen storage disease type IV. Liver biopsy shows diffuse deposition of PAS positive amylopectin like material in hepatocytes (PAS stain).
The only effective therapeutic approach presently available for GSD-IV patients with progressive liver disease is liver transplantation. Liver transplantation may be helpful not only for liver disease but also for muscular involvement[60,119,120]. This may be due to systemic microchimerism after liver allotransplantation and amelioration of pancellular enzyme deficiencies.
References
1.Structure of glycogens and amylopectins. III. Normal and abnormal human glycogen.
ILLINGWORTH B, CORI GT.
J Biol Chem. 1952 Dec;199(2):653-60
2. Familial cirrhosis of the liver with storage of abnormal glycogen.
ANDERSEN DH
Lab Invest. 1956 Jan-Feb; 5(1):11-20.
3. Lack of an alpha-1,4-glucan: alpha-1,4-glucan 6-glycosyl transferase in a case of type IV glycogenosis.
Brown BI, Brown DH.
Proc Natl Acad Sci U S A. 1966 Aug;56(2):725-9.
4. Hum Mol Genet. 2011 Feb 1;20(3):455-65. doi: 10.1093/hmg/ddq492. Epub 2010 Nov 12.
Glycogen-branching enzyme deficiency leads to abnormal cardiac development: novel insights into glycogen storage disease IV.
Lee YC1, Chang CJ, Bali D, Chen YT, Yan YT.
5. Acta Myol. 2011 Oct; 30(2): 96–102.
PMCID: PMC3235878 Progress and problems in muscle glycogenoses
S. DiMauro and R. Spiegel1
6. Hum Mol Genet. 2015 Oct 15;24(20):5667-76. doi: 10.1093/hmg/ddv280. Epub 2015 Jul 21.
7. Neuromusc. Disord. 14: 253-260, 2004. [PubMed: 15019703